Cepheid wins IVDR CE mark for 11-target Xpert GI Panel

Cepheid said on May 13, 2026 that it has received IVDR CE marking in Europe for its Xpert GI Panel, a multiplex PCR assay that runs on GeneXpert systems and detects 11 gastrointestinal pathogens from a single stool sample in Cary-Blair transport media. According to the company, the test delivers results in about 74 minutes, requires less than one minute of hands-on time, and will begin shipping to countries that accept the CE mark in the coming weeks. The panel covers bacterial, viral, and parasitic targets, including Campylobacter, Salmonella, Shigella/EIEC, STEC stx1/stx2, Yersinia enterocolitica, Vibrio cholerae, Vibrio parahaemolyticus, Giardia, Cryptosporidium, and norovirus GI/GII. (prnewswire.com)

Why it matters: For veterinary professionals, the story is less about direct companion-animal use and more about the broader diagnostics trend it reflects: faster, syndromic molecular testing on installed platforms that many human-health labs already use. That matters because multiplex GI panels can shorten time to answers, reduce follow-up testing, and support more targeted treatment and infection-control decisions, though expert groups also stress the need for diagnostic stewardship and careful interpretation of positives in context. In practices and referral settings that coordinate with public health, One Health, or zoonotic disease investigations, the expanding availability of rapid GI molecular panels in human medicine may also shape expectations around turnaround time, pathogen identification, and cross-sector surveillance. (pmc.ncbi.nlm.nih.gov)

What to watch: Watch for the European commercial rollout, any country-specific adoption details, and whether Cepheid expands GI menu strategy further alongside its existing standalone C. difficile and norovirus assays. (prnewswire.com)